Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia

Steffi Van De Ven, Thatjana Gardeitchik, Dorus Kouwenberg, Leo Kluijtmans, Ron Wevers, Eva Morava-Kozicz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although hyperprolinemia type-II has a discriminative metabolic phenotype and is frequently associated with neurological system involvement, the casual relation between the metabolic abnormalities and the clinical features, except for those of the secondary B6 deficiency, has been frequently debated. In order to evaluate disease frequency and the neuro-metabolic outcome we searched our laboratory database between 1992 and 2010, including 20,991 urinary organic acid profiles. From these individuals 16,720 parallel blood samples were available, and were investigated by serum amino acid analysis. We also evaluated the clinical, neurological, psychological features, laboratory data and vitamin levels and therapeutic effect in metabolically confirmed hyperprolinemia. Due to the mitochondrial localization of both ALDH4A1 and PRODH mitochondrial enzyme complex activity was evaluated and oxygen consumption was measured to assess ATP production in patient-fibroblasts. The Mitochondrial Disease Score was used to evaluate clinical mitochondrial dysfunction. The child behavior checklist was used to screen for psychopathology. We found four patients with increased urinary P5C diagnosed with hyperprolinemia type II, and only one patient had hyperprolinemia type I. All children with hyperprolinemia type II had low normal B6 concentration, and three of the patients had biochemical markers suggesting mitochondrial dysfunction. Mitochondrial dysfunction was confirmed in a muscle biopsy in one case. Intellectual disability was found in two adolescent patients. All patients showed seizures and significant behavioral problems, including anxiety and hallucinations. The clinical course was non-progressive and independent from the B6 concentration and B6 therapy. Hyperprolinemia is a rare inborn error. Individuals with hyperprolinemia should be monitored closely due to their frequent behavioral problems.

Original languageEnglish (US)
Pages (from-to)383-390
Number of pages8
JournalJournal of Inherited Metabolic Disease
Volume37
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Therapeutics
Mitochondrial Diseases
Hallucinations
Child Behavior
Therapeutic Uses
Checklist
Psychopathology
Oxygen Consumption
Vitamins
Intellectual Disability
Seizures
Anxiety
Fibroblasts
Adenosine Triphosphate
Biomarkers
Databases
Psychology
Phenotype
Biopsy
Amino Acids

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia. / Van De Ven, Steffi; Gardeitchik, Thatjana; Kouwenberg, Dorus; Kluijtmans, Leo; Wevers, Ron; Morava-Kozicz, Eva.

In: Journal of Inherited Metabolic Disease, Vol. 37, No. 3, 01.01.2014, p. 383-390.

Research output: Contribution to journalArticle

Van De Ven, Steffi ; Gardeitchik, Thatjana ; Kouwenberg, Dorus ; Kluijtmans, Leo ; Wevers, Ron ; Morava-Kozicz, Eva. / Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia. In: Journal of Inherited Metabolic Disease. 2014 ; Vol. 37, No. 3. pp. 383-390.
@article{58d854c4eee14ba6bb3227a0adaacd4b,
title = "Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia",
abstract = "Although hyperprolinemia type-II has a discriminative metabolic phenotype and is frequently associated with neurological system involvement, the casual relation between the metabolic abnormalities and the clinical features, except for those of the secondary B6 deficiency, has been frequently debated. In order to evaluate disease frequency and the neuro-metabolic outcome we searched our laboratory database between 1992 and 2010, including 20,991 urinary organic acid profiles. From these individuals 16,720 parallel blood samples were available, and were investigated by serum amino acid analysis. We also evaluated the clinical, neurological, psychological features, laboratory data and vitamin levels and therapeutic effect in metabolically confirmed hyperprolinemia. Due to the mitochondrial localization of both ALDH4A1 and PRODH mitochondrial enzyme complex activity was evaluated and oxygen consumption was measured to assess ATP production in patient-fibroblasts. The Mitochondrial Disease Score was used to evaluate clinical mitochondrial dysfunction. The child behavior checklist was used to screen for psychopathology. We found four patients with increased urinary P5C diagnosed with hyperprolinemia type II, and only one patient had hyperprolinemia type I. All children with hyperprolinemia type II had low normal B6 concentration, and three of the patients had biochemical markers suggesting mitochondrial dysfunction. Mitochondrial dysfunction was confirmed in a muscle biopsy in one case. Intellectual disability was found in two adolescent patients. All patients showed seizures and significant behavioral problems, including anxiety and hallucinations. The clinical course was non-progressive and independent from the B6 concentration and B6 therapy. Hyperprolinemia is a rare inborn error. Individuals with hyperprolinemia should be monitored closely due to their frequent behavioral problems.",
author = "{Van De Ven}, Steffi and Thatjana Gardeitchik and Dorus Kouwenberg and Leo Kluijtmans and Ron Wevers and Eva Morava-Kozicz",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10545-013-9660-9",
language = "English (US)",
volume = "37",
pages = "383--390",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Long-term clinical outcome, therapy and mild mitochondrial dysfunction in hyperprolinemia

AU - Van De Ven, Steffi

AU - Gardeitchik, Thatjana

AU - Kouwenberg, Dorus

AU - Kluijtmans, Leo

AU - Wevers, Ron

AU - Morava-Kozicz, Eva

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Although hyperprolinemia type-II has a discriminative metabolic phenotype and is frequently associated with neurological system involvement, the casual relation between the metabolic abnormalities and the clinical features, except for those of the secondary B6 deficiency, has been frequently debated. In order to evaluate disease frequency and the neuro-metabolic outcome we searched our laboratory database between 1992 and 2010, including 20,991 urinary organic acid profiles. From these individuals 16,720 parallel blood samples were available, and were investigated by serum amino acid analysis. We also evaluated the clinical, neurological, psychological features, laboratory data and vitamin levels and therapeutic effect in metabolically confirmed hyperprolinemia. Due to the mitochondrial localization of both ALDH4A1 and PRODH mitochondrial enzyme complex activity was evaluated and oxygen consumption was measured to assess ATP production in patient-fibroblasts. The Mitochondrial Disease Score was used to evaluate clinical mitochondrial dysfunction. The child behavior checklist was used to screen for psychopathology. We found four patients with increased urinary P5C diagnosed with hyperprolinemia type II, and only one patient had hyperprolinemia type I. All children with hyperprolinemia type II had low normal B6 concentration, and three of the patients had biochemical markers suggesting mitochondrial dysfunction. Mitochondrial dysfunction was confirmed in a muscle biopsy in one case. Intellectual disability was found in two adolescent patients. All patients showed seizures and significant behavioral problems, including anxiety and hallucinations. The clinical course was non-progressive and independent from the B6 concentration and B6 therapy. Hyperprolinemia is a rare inborn error. Individuals with hyperprolinemia should be monitored closely due to their frequent behavioral problems.

AB - Although hyperprolinemia type-II has a discriminative metabolic phenotype and is frequently associated with neurological system involvement, the casual relation between the metabolic abnormalities and the clinical features, except for those of the secondary B6 deficiency, has been frequently debated. In order to evaluate disease frequency and the neuro-metabolic outcome we searched our laboratory database between 1992 and 2010, including 20,991 urinary organic acid profiles. From these individuals 16,720 parallel blood samples were available, and were investigated by serum amino acid analysis. We also evaluated the clinical, neurological, psychological features, laboratory data and vitamin levels and therapeutic effect in metabolically confirmed hyperprolinemia. Due to the mitochondrial localization of both ALDH4A1 and PRODH mitochondrial enzyme complex activity was evaluated and oxygen consumption was measured to assess ATP production in patient-fibroblasts. The Mitochondrial Disease Score was used to evaluate clinical mitochondrial dysfunction. The child behavior checklist was used to screen for psychopathology. We found four patients with increased urinary P5C diagnosed with hyperprolinemia type II, and only one patient had hyperprolinemia type I. All children with hyperprolinemia type II had low normal B6 concentration, and three of the patients had biochemical markers suggesting mitochondrial dysfunction. Mitochondrial dysfunction was confirmed in a muscle biopsy in one case. Intellectual disability was found in two adolescent patients. All patients showed seizures and significant behavioral problems, including anxiety and hallucinations. The clinical course was non-progressive and independent from the B6 concentration and B6 therapy. Hyperprolinemia is a rare inborn error. Individuals with hyperprolinemia should be monitored closely due to their frequent behavioral problems.

UR - http://www.scopus.com/inward/record.url?scp=84904188432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904188432&partnerID=8YFLogxK

U2 - 10.1007/s10545-013-9660-9

DO - 10.1007/s10545-013-9660-9

M3 - Article

VL - 37

SP - 383

EP - 390

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -